{"id":858785,"date":"2025-06-10T05:48:12","date_gmt":"2025-06-10T09:48:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/"},"modified":"2025-06-10T05:48:12","modified_gmt":"2025-06-10T09:48:12","slug":"shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/","title":{"rendered":"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action &#8211; URGN"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 10, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Levi &amp; Korsinsky, LLP notifies investors in <b>UroGen Pharma Ltd.<\/b> (&#8220;UroGen Pharma Ltd.&#8221; or the &#8220;Company&#8221;) (NASDAQ: URGN) of a class action securities lawsuit.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" title=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" alt=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>CLASS DEFINITION: <\/b>The lawsuit seeks to recover losses on behalf of UroGen Pharma Ltd. investors who were adversely affected by <span>alleged<\/span> securities <span>fraud<\/span> between <span class=\"xn-chron\">July 27, 2023<\/span> and <span class=\"xn-chron\">May 15, 2025<\/span>. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n<p class=\"prntac\">\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4445549-2&amp;h=1055919061&amp;u=https%3A%2F%2Fzlk.com%2Fpslra-1%2Furogen-pharma-ltd-lawsuit-submission-form%3Fprid%3D152225%26wire%3D4&amp;a=https%3A%2F%2Fzlk.com%2Fpslra-1%2Furogen-pharma-ltd-lawsuit-submission-form%3Fprid%3D152225%26wire%3D4\" target=\"_blank\" rel=\"nofollow\">https:\/\/zlk.com\/pslra-1\/urogen-pharma-ltd-lawsuit-submission-form?prid=152225&amp;wire=4<\/a>\u00a0<\/p>\n<p>\n        <b>URGN<\/b>\u00a0investors may also contact <span class=\"xn-person\">Joseph E. Levi, Esq.<\/span> via email <a href=\"mailto:at\u00a0jlevi@levikorsinsky.com\u00a0or\" rel=\"nofollow\">at\u00a0jlevi@levikorsinsky.com\u00a0or<\/a> by telephone at (212) 363-7500.<\/p>\n<p>\n        <b>CASE DETAILS: <\/b>The filed complaint <span>alleges<\/span> that defendants made false statements and\/or concealed that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of the Company&#8217;s lead pipeline product, UGN-102, because it lacked a concurrent control arm; (2) as a result, the Company would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (3) UroGen failed to heed the FDA&#8217;s warnings about the study design used to support a drug application for UGN-102; (4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and (5) as a result of the foregoing, defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>\n<p>\n        <b>WHAT&#8217;S NEXT? <\/b>If you suffered a loss in UroGen Pharma Ltd. during the relevant time frame, you have until <b><span class=\"xn-chron\">July 28, 2025<\/span><\/b>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn&#8217;t require that you serve as a lead plaintiff.<\/p>\n<p>\n        <b>NO COST TO YOU: <\/b>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <b>There is no cost or obligation to participate.<\/b><\/p>\n<p>\n        <b>WHY LEVI &amp; KORSINSKY: <\/b>Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services&#8217; Top 50 Report as one of the top securities litigation firms in <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>\n        <b>CONTACT:<\/b><br \/>\n        <br \/>Levi &amp; Korsinsky, LLP <br \/><span class=\"xn-person\">Joseph E. Levi, Esq.<\/span><br \/><span class=\"xn-person\">Ed Korsinsky, Esq.<\/span><br \/>33 Whitehall Street, 17th Floor<br \/><span class=\"xn-location\">New York, NY<\/span> 10004<br \/><a href=\"mailto:jlevi@levikorsinsky.com\" rel=\"nofollow\">jlevi@levikorsinsky.com<\/a><br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<br \/><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4445549-2&amp;h=322839305&amp;u=https%3A%2F%2Fwww.zlk.com&amp;a=www.zlk.com\" target=\"_blank\" rel=\"nofollow\">www.zlk.com<\/a>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY06532&amp;sd=2025-06-10\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/shareholders-that-lost-money-on-urogen-pharma-ltdurgn-should-contact-levi--korsinsky-about-pending-class-action---urgn-302476984.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/shareholders-that-lost-money-on-urogen-pharma-ltdurgn-should-contact-levi&#8211;korsinsky-about-pending-class-action&#8212;urgn-302476984.html<\/a><\/p>\n<p>SOURCE  Levi &amp; Korsinsky, LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY06532&amp;Transmission_Id=202506100545PR_NEWS_USPR_____NY06532&amp;DateId=20250610\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , June 10, 2025 \/PRNewswire\/ &#8212; Levi &amp; Korsinsky, LLP notifies investors in UroGen Pharma Ltd. (&#8220;UroGen Pharma Ltd.&#8221; or the &#8220;Company&#8221;) (NASDAQ: URGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UroGen Pharma Ltd. investors who were adversely affected by alleged securities fraud between July 27, 2023 and May 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/urogen-pharma-ltd-lawsuit-submission-form?prid=152225&amp;wire=4\u00a0 URGN\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) the ENVISION clinical study was not &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action &#8211; URGN&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-858785","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action - URGN - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action - URGN - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , June 10, 2025 \/PRNewswire\/ &#8212; Levi &amp; Korsinsky, LLP notifies investors in UroGen Pharma Ltd. (&#8220;UroGen Pharma Ltd.&#8221; or the &#8220;Company&#8221;) (NASDAQ: URGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UroGen Pharma Ltd. investors who were adversely affected by alleged securities fraud between July 27, 2023 and May 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/urogen-pharma-ltd-lawsuit-submission-form?prid=152225&amp;wire=4\u00a0 URGN\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) the ENVISION clinical study was not &hellip; Continue reading &quot;Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action &#8211; URGN&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T09:48:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action &#8211; URGN\",\"datePublished\":\"2025-06-10T09:48:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/\"},\"wordCount\":459,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/\",\"name\":\"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action - URGN - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"datePublished\":\"2025-06-10T09:48:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action &#8211; URGN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action - URGN - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action - URGN - Market Newsdesk","og_description":"PR Newswire NEW YORK , June 10, 2025 \/PRNewswire\/ &#8212; Levi &amp; Korsinsky, LLP notifies investors in UroGen Pharma Ltd. (&#8220;UroGen Pharma Ltd.&#8221; or the &#8220;Company&#8221;) (NASDAQ: URGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UroGen Pharma Ltd. investors who were adversely affected by alleged securities fraud between July 27, 2023 and May 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/urogen-pharma-ltd-lawsuit-submission-form?prid=152225&amp;wire=4\u00a0 URGN\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) the ENVISION clinical study was not &hellip; Continue reading \"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action &#8211; URGN\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-10T09:48:12+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action &#8211; URGN","datePublished":"2025-06-10T09:48:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/"},"wordCount":459,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/","name":"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action - URGN - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","datePublished":"2025-06-10T09:48:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-that-lost-money-on-urogen-pharma-ltd-urgn-should-contact-levi-korsinsky-about-pending-class-action-urgn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi &amp; Korsinsky about pending Class Action &#8211; URGN"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=858785"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858785\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=858785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=858785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=858785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}